People with the rarest type of ANCA-associated vasculitis (AAV), called eosinophilic granulomatosis with polyangiitis (EGPA), and AAV patients…
Articles by Marisa Wexler, MS
Biomarkers measured in blood or urine may help track disease activity and organ damage in people with ANCA-associated vasculitis…
About half of people with granulomatosis with polyangiitis (GPA) have impairment of a valve in the…
At ANCA Vasculitis News, we have spent the last year bringing you coverage of the latest developments in research…
Self-reactive anti-neutrophil cytoplasmic antibodies, or ANCAs, may play a unique role in driving blood vessel inflammation in people with eosinophilic…
In a Phase 3 trial of Tavneos (avacopan) in people with ANCA-associated vasculitis (AAV), the therapy’s effectiveness in…
The U.S. Food and Drug Administration has approved Sana Biotechnology’s investigational new drug (IND) application requesting a Phase…
People with ANCA-associated vasculitis (AAV) that affects their kidneys are at a significantly increased risk of kidney failure if…
High blood levels of the immune protein C4 are significantly associated with greater kidney-specific disease activity and a higher chance…
A treatment regimen that combines low-dose glucocorticoids and rituximab is just as effective at controlling ANCA-associated vasculitis (AAV) as…